A new self-assessment from Boehringer Ingelheim comes with some considerable boasting about the potential for new therapies and new indications now in its pipeline. Pradaxa was recently approvedÂ for venous thromboembolism and four other indications are currently in the clinic. Late-stage trials are underway for two experimental cancer therapies, a substance for diabetes type II, and one substance in development for pre-menopausal women with hypoactive sexual desire disorder. R&D spending jumped about 10 percent last year to â‚¬1.7 billion.
"We are very optimistic as our financial basis is sound and our prospects are encouraging," says a supremely confident Boehringer Chairman Dr Alessandro Banchi. "And with the forthcoming new product launches and our products in the pipeline, we have once again proved our company's power of innovation and potential for success."
- check out the press release